CompanyHealthAi
Frontier Medicines
Frontier Medicines is a precision-medicine biotech using chemoproteomics, covalent chemistry, and machine learning to drug proteins long considered 'undruggable.' Its lead candidate, FMC-376, is a first-in-class dual ON/OFF inhibitor of KRAS G12C now in the Phase 1/2 PROSPER trial. Backed by $315M+ in venture funding and a major AbbVie partnership, the company is one of the most-watched names in next-generation targeted cancer therapy.
2018Founded
South San FranciscoHQ
$20MSeries C Extension
biotechnologyprecision-medicinedrug-discoveryoncologykrasundruggable-targets
